Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A H3K27M-targeted vaccine in adults with diffuse midline glioma.
Grassl N, Poschke I, Lindner K, Bunse L, Mildenberger I, Boschert T, Jähne K, Green EW, Hülsmeyer I, Jünger S, Kessler T, Suwala AK, Eisele P, Breckwoldt MO, Vajkoczy P, Grauer OM, Herrlinger U, Tonn JC, Denk M, Sahm F, Bendszus M, von Deimling A, Winkler F, Wick W, Platten M, Sahm K. Grassl N, et al. Among authors: boschert t. Nat Med. 2023 Oct;29(10):2586-2592. doi: 10.1038/s41591-023-02555-6. Epub 2023 Sep 21. Nat Med. 2023. PMID: 37735561 Free PMC article.
NLGN4X TCR transgenic T cells to treat gliomas.
Krämer C, Kilian M, Chih YC, Kourtesakis A, Hoffmann DC, Boschert T, Koopmann P, Sanghvi K, De Roia A, Jung S, Jähne K, Day B, Shultz LD, Ratliff M, Harbottle R, Green EW, Will R, Wick W, Platten M, Bunse L. Krämer C, et al. Among authors: boschert t. Neuro Oncol. 2024 Feb 2;26(2):266-278. doi: 10.1093/neuonc/noad172. Neuro Oncol. 2024. PMID: 37715782 Free PMC article.
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Grassl N, Sahm K, Süße H, Poschke I, Bunse L, Bunse T, Boschert T, Mildenberger I, Rupp AK, Ewinger MP, Lanz LM, Denk M, Tabatabai G, Ronellenfitsch MW, Herrlinger U, Glas M, Krex D, Vajkoczy P, Wick A, Harting I, Sahm F, von Deimling A, Bendszus M, Wick W, Platten M. Grassl N, et al. Among authors: boschert t. Neurol Res Pract. 2023 Oct 19;5(1):55. doi: 10.1186/s42466-023-00282-4. Neurol Res Pract. 2023. PMID: 37853454 Free PMC article.
T-FINDER: A highly sensitive, pan-HLA platform for functional T cell receptor and ligand discovery.
Cetin M, Pinamonti V, Schmid T, Boschert T, Mellado Fuentes A, Kromer K, Lerner T, Zhang J, Herzig Y, Ehlert C, Hernandez-Hernandez M, Samaras G, Torres CM, Fisch L, Dragan V, Kouwenhoven A, Van Schoubroeck B, Wils H, Van Hove C, Platten M, Green EW, Stevenaert F, Felix NJ, Lindner JM. Cetin M, et al. Among authors: boschert t. Sci Adv. 2024 Feb 2;10(5):eadk3060. doi: 10.1126/sciadv.adk3060. Epub 2024 Feb 2. Sci Adv. 2024. PMID: 38306432 Free PMC article.
Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy.
Tan CL, Lindner K, Boschert T, Meng Z, Rodriguez Ehrenfried A, De Roia A, Haltenhof G, Faenza A, Imperatore F, Bunse L, Lindner JM, Harbottle RP, Ratliff M, Offringa R, Poschke I, Platten M, Green EW. Tan CL, et al. Among authors: boschert t. Nat Biotechnol. 2024 Mar 7. doi: 10.1038/s41587-024-02161-y. Online ahead of print. Nat Biotechnol. 2024. PMID: 38454173
Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation.
Heckler M, Ali LR, Clancy-Thompson E, Qiang L, Ventre KS, Lenehan P, Roehle K, Luoma A, Boelaars K, Peters V, McCreary J, Boschert T, Wang ES, Suo S, Marangoni F, Mempel TR, Long HW, Wucherpfennig KW, Dougan M, Gray NS, Yuan GC, Goel S, Tolaney SM, Dougan SK. Heckler M, et al. Among authors: boschert t. Cancer Discov. 2021 Oct;11(10):2564-2581. doi: 10.1158/2159-8290.CD-20-1540. Epub 2021 May 3. Cancer Discov. 2021. PMID: 33941591 Free PMC article.